Informations:
Erreur:
ID
12112
Description
Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line; ODM derived from: https://clinicaltrials.gov/show/NCT02187042
Lien
https://clinicaltrials.gov/show/NCT02187042
Mots-clés
Versions (1)
- 24/09/2015 24/09/2015 - Julian Varghese
Téléchargé le
24 septembre 2015
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Metastatic/Advanced Renal Cell Carcinoma NCT02187042
Eligibility Metastatic/Advanced Renal Cell Carcinoma NCT02187042
- StudyEvent: Eligibility
Similar models
Eligibility Metastatic/Advanced Renal Cell Carcinoma NCT02187042
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Renal Cell Carcinoma; Metastatic to | Renal Cell Carcinoma; Advanced phase | sunitinib
Item
metastatic and/or advanced renal cell carcinoma patients treated with sunitinib in first line according to the summary of product characteristics
boolean
C0007134 (UMLS CUI [1,1])
C0036525 (UMLS CUI [1,2])
C0007134 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
C1176020 (UMLS CUI [3])
C0036525 (UMLS CUI [1,2])
C0007134 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
C1176020 (UMLS CUI [3])
Recovery of Function radiotherapy; surgery
Item
resolution of all adverse event (grade ≤ 1 according to the common terminology criteria for adverse events v 4.3 of june 2010) from a prior treatment by radiotherapy and/or surgery
boolean
C0599766 (UMLS CUI [1])
compliance
Item
patient who can be followed for 6 months
boolean
C1321605 (UMLS CUI [1])
consent; form
Item
patient who has signed a consent form
boolean
C0805443 (UMLS CUI [1,1])
C0514044 (UMLS CUI [1,2])
C0348078 (UMLS CUI [2,1])
C0221198 (UMLS CUI [2,2])
C0514044 (UMLS CUI [1,2])
C0348078 (UMLS CUI [2,1])
C0221198 (UMLS CUI [2,2])
Organizational Affiliation patient affiliated to a national health service
Item
patient affiliated to a national health service
boolean
C0029239 (UMLS CUI [1])
Contraceptive methods | Childbearing Potential
Item
sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception during the course of the study and for 28 days after the last dose of study treatment
boolean
C0700589 (UMLS CUI [1])
C3831118 (UMLS CUI [2])
C3831118 (UMLS CUI [2])
participation in another clinical study
Item
patient who is participating in another clinical study
boolean
C2348568 (UMLS CUI [1])
Home help needed
Item
patient taken in charge by a home help service
boolean
C0578841 (UMLS CUI [1])
brain metastases; symptomatic; not treated
Item
patient with brain metastases not treated or symptomatic
boolean
C0220650 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C0220650 (UMLS CUI [2,1])
C0231220 (UMLS CUI [2,2])
C0332155 (UMLS CUI [1,2])
C0220650 (UMLS CUI [2,1])
C0231220 (UMLS CUI [2,2])
eastern cooperative oncology group
Item
patient with an eastern cooperative oncology group at inclusion > 2
boolean
C1512162 (UMLS CUI [1])
serum creatinine > 1.5 mg/dl
Item
patient with a rate of serum creatinine > 1.5 times the upper limit normal
boolean
C0201976 (UMLS CUI [1])
bilirubin
Item
patient with a rate of bilirubin > 2 mg/dl
boolean
C1557209 (UMLS CUI [1])
aspartate transaminase; alanine transaminase;
Item
patient with a rate of aspartate transaminase (asat) or alanine transaminase (alat) > 2.5 times the upper limit normal or > 5 times the upper limit normal for patients with hepatic metastases
boolean
C0201899 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
C0201836 (UMLS CUI [2])